What should you know about dupilumab EMA?

The European Medicines Agency, or EMA, evaluates medicines for specified uses and provides product information for clinicians and patients. That information covers indications, dosing instructions, warnings, possible adverse effects, and monitoring considerations. An authorisation does not mean the medicine suits every person or every condition. Your local prescriber also considers your diagnosis, age, other treatments, medical history, and the availability of appropriate follow-up. Dupilumab may be used in more than one inflammatory condition, with different instructions for each.

Read the patient information supplied with your prescription and ask your clinician to explain any term you do not understand. Keep a current list of medicines, allergies, eye problems, and recent vaccinations. Follow the prescribed injection schedule and storage instructions; do not borrow doses or alter treatment based on an online summary. For a plain overview of the medicine, see [Dupilumab](/materials/dupilumab/); for care planning, see [Dupilumab Treatment](/treatments/medical-dermatology/dupilumab-therapy/).

Ask for medical advice if you develop persistent eye irritation, eye pain, vision changes, facial redness, or a worsening flare after starting treatment. Seek emergency help for hives with swelling of the mouth or throat, faintness, or breathing difficulty. Report suspected side effects through the route advised by your prescriber or local medicines authority, especially if symptoms are severe or unexpected.

Which authorised use applies to my diagnosis? What benefits and risks matter most for me? Which warnings require urgent contact? How will we monitor my response? Where can I find the current patient information for my prescription?